Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Feb 16, 2021; 9(5): 1087-1095
Published online Feb 16, 2021. doi: 10.12998/wjcc.v9.i5.1087
Effect of rifampicin on anticoagulation of warfarin: A case report
Ya-Ni Hu, Bo-Ting Zhou, Hua-Rong Yang, Qi-Lin Peng, Xu-Rui Gu, Shu-Sen Sun
Ya-Ni Hu, Bo-Ting Zhou, Hua-Rong Yang, Qi-Lin Peng, Xu-Rui Gu, Department of Pharmacy, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China
Bo-Ting Zhou, The Institute of Hospital Pharmacy, Central South University, Changsha 410008, Hunan Province, China
Shu-Sen Sun, College of Pharmacy and Health Sciences, Western New England University, Springfield, MA 31329, United States
Author contributions: Hu YN and Zhou BT were the patient’s pharmacists; Hu YN reviewed the literature and contributed to manuscript drafting; Hu YN, Zhou BT, Yang HR, Peng QL and Gu XR integrated the information from the patient and contributed to the figure; Zhou BT and Sun SS were responsible for revision of the manuscript; the major reviewing and editing were completed by Zhou BT and Hu YN; All authors commented on previous versions of the manuscript and issued final approval for the version to be submitted.
Informed consent statement: The patient agreed to treatment throughout and shared the information through this paper.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bo-Ting Zhou, MD, PhD, Chief Pharmacist, Professor, Department of Pharmacy, Xiangya Hospital, Central South University, No. 87 Xiangya Road, Kaifu District, Changsha 410008, Hunan Province, China. botingzhou0918@126.com
Received: June 9, 2020
Peer-review started: June 9, 2020
First decision: November 30, 2020
Revised: December 22, 2020
Accepted: December 28, 2020
Article in press: December 28, 2020
Published online: February 16, 2021
Processing time: 235 Days and 8.1 Hours
Core Tip

Core Tip: Brucellosis is a zoonotic disease with increasing incidence. In order to improve the adherence and cure rate of outpatients, doxorubicin and rifampicin is the preferred treatment. We described a patient with brucellosis and mechanical valve replacement caused by infective endocarditis who required the combination of rifampicin and warfarin. The case highlighted the racial differences in the therapeutic range of the international normalized ratio and the adjustment range of warfarin dose. Individualized medication is required. Pharmacists can help reduce the burden on doctors and the risk of adverse reactions.